HIMS — Hims & Hers Health, Inc. stock price, charts and financials

QT39Hims & Hers Health, Inc.

Hims & Hers Health, Inc. (NYSE: HIMS) is a Healthcare company in the Medical - Equipment & Services industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
32.16
+1.34+4.35%
OverviewShort InterestFilings
HIMSQT39Hims & Hers Health, Inc.·NYSE
32.16+4.35%
News
Up 4.3% — NYSE: HIMS Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the Firm (globenewswire.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
OMCL-1.33%$37.15DRTS+9.73%$13.08MLAB-3.15%$101.14LAB-5.28%$0.82PTGX+2.67%$135.81HQY+0.58%$104.97CRNX+0.12%$83.86BIO-0.55%$332.88
Snapshot
Index-P/E-EPS (ttm)-0.09Insider Own3.03%Shs Outstand223.08MPerf Week9.69%
Market Cap7.17BForward P/E68.38EPS next Y0.47Insider Trans-4.17%Shs Float208.82MPerf Month-15.99%
Enterprise Value7.55BPEG-EPS next Q-Inst Own-Short Float29.41%Perf Quarter17.93%
Income-12.00MP/S3.03EPS this Y-39.90%Inst Trans-Short Ratio2.56Perf Half Y21.63%
Sales2.37BP/B16.09EPS next Y473.54%ROA-0.58%Short Interest61.41MPerf YTD-0.95%
Book/sh2.00P/C9.55EPS next 5Y-ROE-2.48%52W High65.59 -50.97%Perf Year-48.59%
Cash/sh3.37P/FCF81.69EPS past 3/5Y-ROIC0.66%52W Low13.74 134.06%Perf 3Y272.22%
Dividend Est.-EV/EBITDA-Sales past 3/5Y64.55% 73.58%Gross Margin67.64%Volatility10.72% 8.52%Perf 5Y292.20%
Dividend TTM-EV/Sales3.19EPS Y/Y TTM-116.98%Oper. Margin1.32%ATR (14)2.84Perf 10Y-
Dividend Ex-Date-Quick Ratio1.55Sales Y/Y TTM60.46%Profit Margin-0.56%RSI (14)52.23Recom2.65
Dividend Gr. 3/5Y-Current Ratio1.69EPS Q/Q-300.00%SMA200.59%Beta2.40Target Price26.91
Payout0.00%Debt/Eq2.06Sales Q/Q3.75%SMA503.60%Rel Volume0.60Prev Close30.82
Employees2,442LT Debt/Eq2.06EarningsAug 10SMA2006.96%Avg Volume18.89MPrice32.16
IPO DateSep 13, 2019Option/ShortYes / YesEPS/Sales Surpr.-1676.48% -1.42%Net Debt/EBITDA30.27Volume11,374,829Change4.35%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-09-26ReiteratedUBS$25 → $37
Jul-01-26ReiteratedCanaccord GenuityBuy$32 → $40
Jun-02-26ReiteratedLeerink PartnersMarket Perform$18 → $25
May-26-26ReiteratedUBS$23 → $25
May-22-26ReiteratedUBS$18 → $23
May-12-26ReiteratedJefferiesHold$26 → $25
May-12-26ReiteratedUBS$30 → $35
May-12-26ReiteratedCanaccord GenuityBuy$30 → $32
May-05-26ReiteratedDeutsche BankHold$28 → $25
Mar-10-26ReiteratedDeutsche BankHold$31 → $28
Latest News
Aug-04-26
Aug-04-2607:02PM
NYSE: HIMS Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the Firmglobenewswire.com
03:12PM
Securities Fraud Investigation Into Hims & Hers Health, Inc. (HIMS) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruzglobenewswire.com
Aug-03-26
Aug-03-2608:00PM
Kaplan Fox Announces a Securities Investigation into Hims & Hers Health, Inc. (HIMS) - Investors Encouraged to Contact the Firmnewsfilecorp.com
03:53PM
Is Hims & Hers Health Stock in Trouble?fool.com
02:07PM
NYSE: HIMS Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the Firmbusinesswire.com
Jul-31-26
Jul-31-2602:41PM
Hims & Hers Shares Rebound Friday: What's Driving the Move?benzinga.com
Jul-30-26
Jul-30-2611:14PM
Hims & Hers Health: Still An Undervalued Company With Tremendous Upsideseekingalpha.com
09:38PM
Is The Sharp Drop In Hims & Hers Health Stock A Reason To Buy?Yahoo
02:30PM
Kaplan Fox Alerts Investors of Hims & Hers Health, Inc. (HIMS) to an Investigation of Potential Securities Law Violationsnewsfilecorp.com
01:58PM
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with SBS Lawbusinesswire.com
11:00AM
Securities Fraud Investigation Into Hims & Hers Health, Inc. (HIMS) Announced -- Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firmgurufocus.com
10:00AM
Hims & Hers Health: FTC Panic Giftseekingalpha.com
10:00AM
Hims & Hers Health, Inc. (HIMS) Shareholders Who Lost Money -- Contact Law Offices of Howard G. Smith About Securities Fraud Investigationgurufocus.com
09:30AM
FTC sues Hims & Hers for allegedly sharing patients' medical data with advertisers Meta and Snaptechcrunch.com
Jul-29-26
Jul-29-2606:06PM
HIMS INVESTOR ALERT: Investigation of Hims & Hers Health, Inc. Announced by Holzer & Holzer, LLCglobenewswire.com
Company

Hims & Hers Health, Inc. operates a comprehensive digital health platform that seamlessly links individuals with licensed medical professionals for virtual consultations and ongoing care. Through its user-friendly websites and mobile app, the company delivers a diverse portfolio of health and wellness solutions directly to consumers. This includes access to recurring prescription medications, alongside a wide selection of over-the-counter drugs, devices, cosmetics, and dietary supplements. Its core focus areas are general wellness, sexual health, skincare, and hair care. Specific non-prescription offerings span categories such as: Wellness: encompassing items like vitamin C, melatonin, biotin, and collagen protein supplements. Skincare: including products such as moisturizers, serums, and face washes. Sexual Health: providing essentials like condoms, climax delay sprays and wipes, vibrators, and lubricants. Hair Care: offering specialized shampoos, conditioners, scalp scrubs, and topical treatments like minoxidil. Beyond direct sales, Hims & Hers also distributes health and wellness products via wholesale partnerships. The company's headquarters are located in San Francisco, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue2,3702,3481,47787252727214983
Cost of Goods Sold Incl. D&A767614303157118673938
Gross Profit1,6021,7331,17371540920410945
Selling, General and Administrative Excl. Other1,2441,192847576371250113119
Research and Development16714979482922110
Other Operating Expense160287185120774810
Operating Income3210662-29-69-115-15-74
Interest Expense
00000000
Unusual Expense
————————
Non-Operating Income (Expense)-701810834-33
Net Income Before Taxes-3912472-22-66-111-18-72
Income Taxes-25-4-5420-300
Consolidated Net Income-12128126-24-66-108-18-72
Net Income From Continuing Operations-12128126-24-66-108-18-72
Net Income-12128126-24-66-108-18-72
EPS (Recurring)-0.050.570.58-0.11-0.32-0.58-0.51-2.07
EPS (Basic, Before Extraordinaries)-0.050.570.58-0.11-0.32-0.58-0.51-2.07
EPS (Diluted)-0.090.510.53-0.11-0.32-0.58-0.51-2.07
EBITDA2917889-12-58-107-14-71
Other After Tax Adjustments
————————
Stock Option Compensation Expense
————————
Price To Earnings Ratio—63.6745.62—————
Price To Sales Ratio3.093.113.542.132.494.503.434.17
Gross Margin67.5973.8179.4282.0077.6175.0073.1554.22
Operating Margin1.354.514.20-3.33-13.09-42.28-10.07-89.16
Net Margin-0.515.458.53-2.75-12.52-39.71-12.08-86.75
Shares Outstanding2282252162092051873535
Market Capitalization7,3327,3065,2231,8601,3141,225511347
Operating Lease Expense
————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$73.93$57.14$40.35$23.56$6.77● Close Price0.00M7.36M14.72M22.09M29.45MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Okupe OluyemiChief Financial OfficerJul 17 '26Sale31.997,163229,168284,321Jul 20
Okupe OluyemiChief Financial OfficerJul 17 '26Option Exercise5.017,16335,887291,484Jul 20
Okupe OluyemiChief Financial OfficerJul 06 '26Sale36.497,163261,351284,321Jul 07
Okupe OluyemiChief Financial OfficerJul 06 '26Option Exercise5.017,16335,887291,484Jul 07
Okupe OluyemiChief Financial OfficerJun 22 '26Option Exercise5.016,37631,944302,518Jun 23
Okupe OluyemiChief Financial OfficerJun 22 '26Sale34.0318,197619,217284,321Jun 23
Carroll Patrick HarrisonChief Medical OfficerJun 18 '26Sale35.0023,726830,410181,861Jun 23
Elshenawy MohamedCTOJun 17 '26Sale31.5030,040946,260101,023Jun 17
Chi MichaelChief Operating OfficerJun 17 '26Sale31.5014,027441,851432,124Jun 17
Becklund IrenePAOJun 17 '26Sale31.504,490141,4356,790Jun 17
Becklund IrenePAOJun 16 '26Sale30.257,573229,08311,280Jun 17
Okupe OluyemiChief Financial OfficerJun 15 '26Option Exercise0.00143,2320335,683Jun 17
Autor Deborah M.Chief Policy OfficerJun 15 '26Option Exercise0.0032,919064,357Jun 17
Chi MichaelChief Operating OfficerJun 15 '26Option Exercise0.00172,5280493,850Jun 17
Becklund IrenePAOJun 15 '26Option Exercise0.0031,942058,197Jun 17
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.